SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Lisa F. Potts, Hao Wu, Arun Singh, Irene Marcilla, Maria R. Luquin, Stella M. Papa, Modeling Parkinson's disease in monkeys for translational studies, a critical analysis, Experimental Neurology, 2014, 256, 133

    CrossRef

  2. 2
    Amaal AlDakheel, Lorraine V. Kalia, Anthony E. Lang, Pathogenesis-Targeted, Disease-Modifying Therapies in Parkinson Disease, Neurotherapeutics, 2014, 11, 1, 6

    CrossRef

  3. 3
    Weidong Le, Role of iron in UPS impairment model of Parkinson's disease, Parkinsonism & Related Disorders, 2014, 20, S158

    CrossRef

  4. 4
    Fabrizio Stocchi, Therapy for Parkinson’s Disease: What is in the Pipeline?, Neurotherapeutics, 2014, 11, 1, 24

    CrossRef

  5. 5
    Fabrizio Stocchi, C. Warren Olanow, Obstacles to the Development of a Neuroprotective Therapy for Parkinson's Disease, Movement Disorders, 2013, 28, 1
  6. 6
    Xiaoyu Sun, Zhongkui Xiong, Yongfang Zhang, Ya Meng, Gang Xu, Zhiming Xia, Jiamei Li, Rui Zhang, Zunji Ke, Zongqin Xia, Yaer Hu, Harpagoside attenuates MPTP/MPP+ induced dopaminergic neurodegeneration and movement disorder via elevating glial cell line-derived neurotrophic factor, Journal of Neurochemistry, 2012, 120, 6
  7. 7
    Wenju Wang, Maosheng Sun, Hongjun Li, Wanpu Wang, Min Yan, The delivery of tyrosine hydroxylase accelerates the neurorestoration of Macaca Rhesus model of Parkinson's disease provided by Neurturin, Neuroscience Letters, 2012, 524, 1, 10

    CrossRef

  8. 8
    Kurt A. Jellinger, The role of α-synuclein in neurodegeneration — An update, Translational Neuroscience, 2012, 3, 2, 75

    CrossRef

  9. 9
    Yue Yong, Hanqing Ding, Zhiqin Fan, Jia Luo, Zun-Ji Ke, Lithium Fails to Protect Dopaminergic Neurons in the 6-OHDA Model of Parkinson’s Disease, Neurochemical Research, 2011, 36, 3, 367

    CrossRef

  10. 10
    C. Warren Olanow, Karl Kieburtz, Defining disease-modifying therapies for PD—A road map for moving forward, Movement Disorders, 2010, 25, 12
  11. 11
    Wei-Bin Shen, Kimberly A. McDowell, Aubrey A. Siebert, Sarah M. Clark, Natalie V. Dugger, Kimberly M. Valentino, H. A. Jinnah, Carole Sztalryd, Paul S. Fishman, Christopher A. Shaw, M. Samir Jafri, Paul J. Yarowsky, Environmental neurotoxin-induced progressive model of parkinsonism in rats, Annals of Neurology, 2010, 68, 1
  12. 12
    Chao Li, Yuan Guo, Wenjie Xie, Xingang Li, Joseph Janokovic, Weidong Le, Neuroprotection of Pramipexole in UPS Impairment Induced Animal Model of Parkinson’s Disease, Neurochemical Research, 2010, 35, 10, 1546

    CrossRef

  13. 13
    Wenjie Xie, Xuping Li, Chao Li, Wen Zhu, Joseph Jankovic, Weidong Le, Proteasome inhibition modeling nigral neuron degeneration in Parkinson’s disease, Journal of Neurochemistry, 2010, 115, 1
  14. 14
    K.Y. Chau, J.M. Cooper, A.H.V. Schapira, Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells, Neurochemistry International, 2010, 57, 5, 525

    CrossRef

  15. 15
    Isabel Ubeda-Bañon, Daniel Saiz-Sanchez, Carlos de la Rosa-Prieto, Alicia Mohedano-Moriano, Noelia Fradejas, Soledad Calvo, Lucia Argandoña-Palacios, Susana Garcia-Muñozguren, Alino Martinez-Marcos, Staging of α-synuclein in the olfactory bulb in a model of Parkinson's disease: Cell types involved, Movement Disorders, 2010, 25, 11
  16. 16
    Kurt A. Jellinger, Parkinson's Disease,
  17. 17
    C. Warren Olanow, Anthony E. Lang, Prospects for Neuroprotective Therapies that can Modulate Non-Dopaminergic Features in Parkinson's Disease,